GlycoMimetics Appoints Dr. Myra Rosario Herrle as Vice President, Regulatory Affairs
April 07 2020 - 9:15AM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that veteran
regulatory expert Myra Rosario Herrle, PhD, RPh, RAC, has joined
the executive management team as Vice President, Regulatory
Affairs.
“We look forward to leveraging Myra’s extensive regulatory
expertise as we continue to progress our pipeline of novel,
small-molecule glycomimetic therapeutics,” said Chief Executive
Officer Rachel King. “Her guidance will be particularly welcome as
we continue our ongoing Phase 3 registration trial of uproleselan
in relapsed or refractory acute myeloid leukemia (AML), and work in
collaboration with the National Cancer Institute (NCI) on the
institute’s multi-center Phase 3 trial to evaluate the drug
candidate in newly-diagnosed patients fit for chemotherapy.”
Dr. Herrle brings 25 years of pharmaceutical industry experience
– with 15 years of regulatory experience and a deep background in
oncology -- to her role at GlycoMimetics. Most recently, she served
as Senior Director, Oncology Global Regulatory Strategy at AbbVie.
Previously, she held positions of increasing responsibility at
Novartis Pharmaceuticals Corporation, including Associate Director
of Oncology Regulatory Affairs, Global Program Regulatory Director
and Global Therapeutic Area Lead (Executive Director). Prior to
Novartis, she was the Therapeutic Area Lead/Director of Oncology at
Glaxo Wellcome/GlaxoSmithKline, focusing on oncology,
musculoskeletal and inflammatory diseases.
About Uproleselan (GMI-1271)
Discovered and developed by GlycoMimetics, uproleselan is
investigational, first-in-class, targeted inhibitor of E-selectin.
Uproleselan (yoo’ pro le’ sel an), currently in a comprehensive
Phase 3 development program in AML, has received Breakthrough
Therapy Designation from the U.S. Food and Drug Administration
(FDA) for the treatment of adult AML patients with relapsed or
refractory disease. Uproleselan is designed to block E-selectin (an
adhesion molecule on cells in the bone marrow) from binding with
blood cancer cells as a targeted approach to disrupting
well-established mechanisms of leukemic cell resistance within the
bone marrow microenvironment. In a Phase 1/2 clinical trial,
uproleselan was evaluated in both newly diagnosed elderly and
relapsed or refractory patients with AML. In both populations,
patients treated with uproleselan together with standard
chemotherapy achieved better-than-expected remission rates and
overall survival compared to historical controls, which have been
derived from results from third-party clinical trials evaluating
standard chemotherapy, as well as lower-than-expected
induction-related mortality rates. Treatment in these patient
populations was generally well-tolerated, with fewer than expected
adverse effects.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused
on the discovery and development of novel glycomimetic drugs to
address unmet medical needs resulting from diseases in which
carbohydrate biology plays a key role. GlycoMimetics’ wholly-owned
drug candidate, uproleselan, an E-selectin antagonist, was
evaluated in a Phase 1/2 clinical trial as a potential treatment
for AML and is being evaluated across a range of patient
populations including a Company-sponsored Phase 3 trial in
relapsed/refractory AML. GlycoMimetics has also completed a Phase 1
clinical trial with another wholly-owned drug candidate, GMI-1359,
a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn
more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the clinical development and potential benefits and impact of the
Company’s drug candidates. These forward-looking statements include
those relating to the planned clinical development of the Company’s
wholly-owned product candidates and the receipt of data from
Pfizer’s Phase 3 clinical trial of rivipansel. Actual results may
differ materially from those in these forward-looking statements.
For a further description of the risks associated with these
statements, as well as other risks facing GlycoMimetics, please see
the risk factors described in the Company’s annual report on Form
10-K filed with the U.S. Securities and Exchange Commission (SEC)
on February 28, 2020, and other filings GlycoMimetics makes with
the SEC from time to time. Forward-looking statements speak only as
of the date of this release, and GlycoMimetics undertakes no
obligation to update or revise these statements, except as may be
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200407005486/en/
Investor Contact: Shari Annes Phone: 650-888-0902 Email:
sannes@annesassociates.com
Media Contact: Jamie Lacey-Moreira Phone: 410-299-3310 Email:
jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024